SEKISUI Diagnostics has announced the launch of the OSOM® RSV Test, a new rapid diagnostic tool designed for professional healthcare settings to detect Respiratory Syncytial Virus (RSV). This immunochromatographic assay provides qualitative results in just 15 minutes using anterior nasal swab specimens. It is CLIA-waived for point-of-care use and, like other OSOM® Rapid Tests, is manufactured in the USA and backed by a team of experienced medical technologists.
What sets the OSOM® RSV Test apart is its targeted use for two high-risk populations: children aged 6 months to 6 years and adults aged 60 and older. These groups are particularly vulnerable to severe RSV infections, and the test's approval for these demographics makes it a valuable tool for timely and accurate diagnosis in busy clinical environments.
“With the overlapping symptoms of respiratory illnesses and varied treatment protocols, timely diagnosis is essential,” said Harold Chan, VP & General Manager of the Point-of-Care Business Unit. “Expanding our respiratory test portfolio supports healthcare professionals in making informed decisions to improve patient outcomes.”
In addition to its clinical utility, the OSOM® RSV Test includes SEKISUI’s unique QC Inside® feature, which adds two extra tests per kit for external quality control at no additional cost. This helps providers meet laboratory compliance requirements while optimizing operational efficiency and cost-effectiveness.
SEKISUI Diagnostics continues to offer a broad range of rapid diagnostic solutions through its OSOM®, Metrix®, and Acucy® brands, serving both professional and home testing markets. With the introduction of the OSOM® RSV Test, the company reinforces its commitment to enhancing diagnostic capabilities at the point of care.